Immix Biopharma (IMMX) Update / Briefing June 03, 2025 03:00 PM ET Speaker0 Thank you for joining us for this Key opinion leader event following ASCO twenty twenty five oral presentation of NXC two zero one Nexicar two trial interim results in relapsedrefractory AL amyloidosis that's just concluded. Here's the requisite disclaimers. And here's the agenda for today's event. First part will be led by doctor Raza who who'll share the unmet clinical need in relapsedrefractory AL amyloidosis and current treatmen ...